BIM 23197

Also Known As:

BIM-23197; N-(N'-(2-hydroxyethyl)-piperazinyl)-2-ethylsulfonyl-Phe-Cys-Tyr-Trp-Lys-Abu-Cys-Thr-NH2 disulfide; N-(N'-(2-hydroxyethyl)piperazinyl)-2-ethylsulfonyl-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-2-aminobutanoyl-cysteinyl-threoninamide disulfide

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - BIM 23197: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - BIM 23197: 5

Experts

1.	Culler, M D: 2 articles (01/2001 - 02/2000)
2.	Enjalbert, A: 2 articles (01/2001 - 02/2000)
3.	Fina, F: 2 articles (01/2001 - 02/2000)
4.	Gunz, G: 2 articles (01/2001 - 02/2000)
5.	Jaquet, P: 2 articles (01/2001 - 02/2000)
6.	Moreau, J P: 2 articles (01/2001 - 02/2000)
7.	Saveanu, A: 2 articles (01/2001 - 02/2000)
8.	Cap, J: 1 article (06/2003)
9.	Cerman, J: 1 article (06/2003)
10.	Hana, V: 1 article (06/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2001 - "In these tumors the suppression of GH release was similarly achieved at picomolar ranges by octreotide, BIM-23197, and BIM-23244 (EC(50) = 25 +/- 15, 3 +/- 2, and 3 +/- 3 pmol/L, respectively). " 04/01/1998 - "Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer." 02/01/2000 - "In the present study the quantitative expression of messenger ribonucleic acid (mRNA) for the 5 SSTR subtypes and the inhibitory effects of SRIF14; SRIF28; octreotide; the SSTR2-preferential analog, BIM-23197; and the SSTR5-preferential analog, BIM-23268, on GH and PRL secretion were analyzed in cells cultured from 15 acromegalic tumors. " 09/01/1999 - "The present study examines the quantitative profile of SSTRs messenger ribonucleic acid (mRNA) in 10 PRL-secreting tumors and correlates the expression with the ability of native somatostatins (SS14 and SS28), SSTR2 preferential analogs (octreotide and BIM-23197), and the SSTR5 preferential analog BIM-23268 to suppress PRL secretion. " 01/01/2001 - "In the present study we quantified SSTR2 and SSTR5 mRNA expression and the GH-suppressive effects of somatostatin-14; octreotide; a SSTR2-preferential compound, BIM-23197; a SSTR5-preferential compound, BIM-23268; and a new SSTR2- and SSTR5-bispecific compound, BIM-23244, in GH-secreting tumors classified as either full responders to octreotide (n = 5) or partially sensitive to octreotide (n = 5). "
2.	Adenoma (Adenomas) 06/01/2003 - "2. The GH secretion in six adenomas was suppressed significantly more (p < 0.01 or p < 0.001 using Mann-Whitney U-test in concentration range of 10(-12) to 10(-8) mol/l) with SSTR2 specific analogue BIM-23197 with no additive effect of compounds combination. " 06/01/2003 - "3. In three adenomas the potency of BIM-23197 and BIM-23268 was almost equal and the combination of these SSTR2 and SSTR5 specific compounds had statistically significant additive effect (p < 0.05 or p < 0.01 in concentration range of 10(-12) to 10(-8) mol/l). " 02/01/2000 - "In cells cultured from adenomas taken from patients partially responsive to the SRIF analog, octreotide, partial additivity in suppressing both GH and PRL secretion was observed when the SSTR2- and SSTR5-preferring analogs, BIM-23197 and BIM-23268, were tested in combination. "
3.	Acromegaly 04/01/1998 - "Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer."

Related Drugs and Biologics

1.	BIM 23268
2.	Octreotide (Sandostatin)
3.	Messenger RNA (mRNA)
4.	RNA (Ribonucleic Acid)
5.	Somatostatin (Somatotropin Release-Inhibiting Factor)
6.	BIM-23244
7.	BIM 23190
8.	lanreotide (Somatuline)